• Investment World
• eWorld
• Catalyst
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Port Info

• Ships in Ports
  
  

Archives

• Yesterday
• Datewise
• Resources

Group Sites

• The Hindu
• Business Line
• The Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Bangalore , April 25

MEDIBIC, a Japanese biotechnology company supporting genomic-based drug discovery, is keen on expanding its presence in India through more partnerships.

The company also wants to further consolidate its existing partnership with the Bangalore-based Strand Genomics, a life sciences informatics company focused on software for drug discovery and development.

Mr Yasuhiro Hashimoto, President and CEO of MediBic, said, "We met several Indian companies and would take a view about final partnership at the appropriate time." He declined to give the investment figures for tie-ups. Japan has a huge potential for Indian companies, as it has the second largest `ethical' drugs (non-over-the counter) market after the US, he said.

Talking to reporters on the sidelines of the Bangalore Bio 2005 here on Sunday, Mr Hashimoto said that MediBic hopes to expand tie-ups with Indian companies to offer customised data analysis through bio-informatics solutions to Japanese pharma companies.

"We have many clients who are interested in getting data on cell functions for drug discovery," he said.

Japan, which entered the bio-technology sector in a big way only recently, hopes to cash in on the revolution for which the Japanese Government is also giving support, Mr Hashimoto said.

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Robotics workshop for children

Copyright © 2005, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line